Ahead of the Curve T wenty-six years ago, as a medical resident, I admitted a 55-year-old man with a large anterior-wall myocardial infarction. He had been previously "healthy," although he had smoked one pack of cigarettes a day for 30 years. We treated him with lidocaine and nitroglycerine. On his eighth hospital day, he died suddenly of an autopsy-proven myocardial rupture .Five years ago, as an attending cardiologist, I admitted a 76-year-old woman with a non-ST segment elevation myocardial infarction. She was overweight and had well-controlled hypertension, but she did not have diabetes. Given elevated levels of troponin T, we arranged coronary angiography, which showed a thrombus-laden lesion in her proximal circumfl ex artery, where my interventional colleague placed a stent. An echocardiogram showed left ventricular hypertrophy, preserved systolic function, impaired diastolic function, and moderate aortic stenosis. She was discharged on aspirin, clopidogrel, metoprolol, enalapril, and atorvastatin, and was referred to cardiac rehabilitation. Her outpatient physicians planned to focus on adherence and to monitor for other cardiac problems, as she was at risk for developing heart failure (with preserved ejection fraction), symptomatic aortic stenosis, and atrial fi brillation.These two stories are indicative of the "cardiac revolution," refl ecting the accomplishments and challenges of modern cardiovascular medicine. During the past few decades, we have seen dramatic declines in the incidence of cardiovascular death 1 and myocardial infarction. 2 Supported by government and industry, countless teams of basic, translational, clinical, and population scientists developed new paradigms for predicting, preventing, and treating disease. Meanwhile, Americans are getting older, fatter, and ethnically more diverse. Rheumatic heart disease and ST-elevation myocardial infarction are "giving way" to heart failure, degenerative valve disease, and atrial fi brillation.Over the past 50 years, we have seen dramatic changes in cardiovascular science and clinical care, accompanied by marked declines in the morbidity and mortality. Nonetheless, cardiovascular disease remains the leading cause of death and disability in the world, and its nature is changing as Americans become older, fatter, and ethnically more diverse. Instead of young or middle-aged men with ST-segment elevation myocardial infarction, the "typical" cardiac patient now presents with acute coronary syndrome or with complications related to chronic hypertension or ischemic heart disease, including heart failure, sudden death, and atrial fi brillation. Analogously, structural heart disease is now dominated by degenerative valve or congenital disease, far more common than rheumatic disease. The changing clinical scene presents cardiovascular scientists with a number of opportunities and challenges, including taking advantage of high-throughput technologies to elucidate complex disease mechanisms, accelerating development and implementation of evidence-based str...